Mr. Chair, yes, I am aware, and that is a serious issue for, particularly, MS patients. It is important that they have this opportunity. However, when they are left to the, I guess, whims of whatever happens in a particular study and then they are unable to access a particular treatment because of another side effect, then that is a serious issue. I do agree with her. We need to do everything we can to ensure MS patients can assess the treatment they so desperately need.
In the House of Commons on June 14th, 2010. See this statement in context.